Incyte Stock News

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ASH24--Incyte to Spotlight New Data, Including a Late Breaking Oral Presentation for Tafasitamab in Follicular Lymphoma, at the 2024 ASH Annual Meeting.

Incyte (INCY) led S&P 500 decliners Tuesday afternoon after the pharmaceutical firm said it will stop developing one drug and pause enrollment in the study of another.

The biopharmaceutical company provided disappointing updates on two research studies.

Incyte stock tumbled Tuesday after the company scrapped one drug and paused enrollment in the study of another. The post Incyte Collapses.

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs.

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).

None of our picks is Nvidia or Amazon or Tesla. Investors may wish to widen the aperture to find the best stocks for outsize earnings growth.

Incyte reported strong Q3 revenue growth, mainly driven by Jakafi and Opzelura, with a 24% increase year-over-year. New product approvals, like Niktimvo, should diversify Incyte's revenue and reduce reliance on Jakafi. The EPS miss is mostly related to elevated R&D spending, which will be critical to ease investors' fears about a potential loss of revenue from Jakafi in the coming years.